CSL First-Half Profit Jumps on Blood-Based Therapies

CSL Ltd., Australia’s biggest pharmaceutical company, reported a 24 percent increase in first- half profit as demand for blood-derived treatments increased.

Net income climbed to $627 million in the six months ended Dec. 31 from $504 million a year earlier, Melbourne-based CSL said today. Sales jumped 11 percent to $2.48 billion.

Demand for immunoglobulin products, which raise infection- fighting antibody levels, and royalties earned from treatments such as Merck & Co.’s Gardasil cervical-cancer vaccine boosted earnings.

Earnings were reported before the start of trading in Australia. CSL rose 0.4 percent to A$57.24 at the close of trading in Sydney yesterday. The shares have advanced 6.2 percent this year, trailing a 6.7 percent increase in Australia’s S&P/ASX 200 index.

CSL surged 68 percent last year, making it the best performing stock in the S&P/ASX 20, which typically includes the nation’s 20 largest stocks.

The company said full-year earnings-per-share will rise about 24 percent.

To contact the reporter on this story: Jason Gale in Melbourne at j.gale@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.